Summary: This publication reports only the baseline characteristics of SYNCHRONIZE-1, a phase 3 trial of the glucagon/GLP-1 dual agonist survodutide in 725 adults with obesity without type 2 diabetes across 14 countries. Efficacy and safety results are not yet available.
PICO Summary
| Element | Detail |
|---|---|
| Population | 725 adults aged ≥18 with BMI ≥30, or ≥27 with at least one obesity complication, without type 2 diabetes (14 countries). Mean age 47.1, BMI 37.9, waist 115.2 cm, 59.4% female; hypertension 40.0%, dyslipidaemia 33.7%, prediabetes 30.2%. |
| Intervention | Once-weekly subcutaneous survodutide up-titrated to 3.6 or 6.0 mg for 76 weeks. |
| Comparison | Placebo once weekly (1:1:1 randomisation across the two doses and placebo). |
| Outcome | Primary endpoints (percent body-weight change and ≥5% weight reduction at Week 76) are not yet reported. This paper establishes baseline comparability only. |
Expert Commentary
It is worth being clear at the outset about what this is: a baseline-characteristics paper, not a results paper, so there is no efficacy verdict to give and any reader hoping to learn whether survodutide works will have to wait. What it does offer is a look at the cohort, a representative Class II obesity population with the usual heavy comorbidity load and a genuinely useful 20% East Asian enrolment, which matters because obesity phenotypes and drug responses differ across ancestry. The glucagon component is the interesting part of survodutide’s design, plausibly adding hepatic lipid oxidation and energy expenditure to GLP-1 effects, with phase 2 hinting at 18 to 19% weight loss. But I will not pre-judge a 76-week trial from its enrolment table. Can I use this with my patients? Not yet, and I would resist letting a baseline paper generate premature enthusiasm. If a patient asks, I can say survodutide is a promising dual agonist in late-stage testing with results pending. I look forward to the Week 76 efficacy and safety data, which is the point at which this trial will actually inform practice.
References
le Roux CW, Wharton S, Bozkurt B, et al. Survodutide for treatment of obesity: baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE-1). Diabetes Obes Metab. 2025;28(1):337–346. doi:10.1111/dom.70196